Chabba Nimisha, Silwal Pushkar Raj, Bascaran Covadonga, Murphy Rinki, Gordon Iris, Mwangi Nyawira, Bhatta Subash, Pant Nayana, Burton Matthew J, Keel Stuart, Evans Jennifer, Ramke Jacqueline
School of Optometry and Vision Science, University of Auckland, Auckland, New Zealand
School of Optometry and Vision Science, University of Auckland, Auckland, New Zealand.
BMJ Open. 2025 Mar 29;15(3):e092081. doi: 10.1136/bmjopen-2024-092081.
Diabetic retinopathy is one of the leading causes of vision impairment globally. Alongside the systemic control of diabetes and timely detection of diabetic retinopathy, the prompt initiation and completion of treatment is essential to prevent vision loss. Routine monitoring of access to retinal screening services for the detection of diabetic retinopathy is common, while monitoring of coverage of subsequent treatment services is far less common. When diabetic retinopathy treatment coverage is assessed, there is great variability in how it is defined and reported. If a definition of treatment coverage could be standardised, the monitoring of the quality of diabetes eye care could more readily be compared between settings and over time. The aim of this review is to summarise how diabetic retinopathy treatment coverage has been measured in published studies and the extent to which these have been disaggregated by population groups.
A search will be conducted on Medline and Embase without any language restrictions, for cohort and cross-sectional studies published from 1 January 2015 that report diabetic retinopathy treatment coverage for adults with diabetic retinopathy and/or macular oedema. We will include studies from any world region reporting diabetic retinopathy treatment coverage for one or more of: (1) laser photocoagulation; (2) intravitreal injections of antivascular endothelial growth factor agents; (3) intravitreal injections of corticosteroids; (4) vitrectomy. The PROGRESS framework (place of residence, race/ethnicity/culture/language, occupation, gender/sex, religion, education, socioeconomic status and social capital) will be used to assess disaggregation by population groups. Two investigators will independently screen studies and extract relevant data. Data will be synthesised descriptively to outline the full range of definitions of diabetic retinopathy treatment coverage in the literature and identify the common sources of data used.
This review will only include published data; thus, no ethical approval will be sought. The findings of this review will be published in a peer-reviewed journal and presented at relevant conferences. The findings will also be considered in conjunction with an ongoing review on retinal screening for diabetic retinopathy to develop indicators for monitoring of services along the diabetes eye care pathway, which may include an indicator of effective service coverage.
Open Science Framework registration 6/08/2024: https://osf.io/5b93m.
糖尿病视网膜病变是全球视力损害的主要原因之一。除了对糖尿病进行系统控制和及时检测糖尿病视网膜病变外,及时开始并完成治疗对于预防视力丧失至关重要。对用于检测糖尿病视网膜病变的视网膜筛查服务的可及性进行常规监测很常见,而对后续治疗服务的覆盖情况进行监测则要少见得多。在评估糖尿病视网膜病变治疗覆盖率时,其定义和报告方式存在很大差异。如果能够标准化治疗覆盖率的定义,那么就可以更轻松地比较不同地区以及不同时间的糖尿病眼部护理质量监测情况。本综述的目的是总结已发表研究中如何衡量糖尿病视网膜病变治疗覆盖率,以及这些研究按人群组进行分类的程度。
将在Medline和Embase上进行检索,无语言限制,检索2015年1月1日以来发表的队列研究和横断面研究,这些研究报告了糖尿病视网膜病变和/或黄斑水肿成人患者的糖尿病视网膜病变治疗覆盖率。我们将纳入来自世界任何地区的研究,这些研究报告了以下一种或多种情况的糖尿病视网膜病变治疗覆盖率:(1)激光光凝;(2)玻璃体内注射抗血管内皮生长因子药物;(3)玻璃体内注射皮质类固醇;(4)玻璃体切除术。将使用PROGRESS框架(居住地、种族/民族/文化/语言、职业、性别、宗教、教育、社会经济地位和社会资本)来评估按人群组进行的分类情况。两名研究人员将独立筛选研究并提取相关数据。将对数据进行描述性综合分析,以概述文献中糖尿病视网膜病变治疗覆盖率的所有定义,并确定所使用的数据的常见来源。
本综述仅纳入已发表的数据;因此,无需寻求伦理批准。本综述的结果将发表在同行评审期刊上,并在相关会议上展示。这些结果还将与正在进行的糖尿病视网膜病变视网膜筛查综述相结合进行考虑,以制定糖尿病眼部护理路径上服务监测指标,其中可能包括有效服务覆盖率指标。
开放科学框架注册日期2024年8月6日:https://osf.io/5b93m 。